High dose Nutrizym 22 in cystic fibrosis

Area of Science:

• Pediatric Gastroenterology
• Cystic Fibrosis Research
• Pharmacological Efficacy Studies

Background:

• Cystic Fibrosis (CF) is a genetic disorder affecting multiple organs, notably the pancreas.
• Pancreatic enzyme replacement therapy (PERT) is crucial for managing maldigestion in CF patients.
• Optimizing PERT dosage and formulation is an ongoing area of clinical research.

Purpose of the Study:

• To compare the efficacy of a new high-dose pancreatic enzyme preparation (Nutrizym 22) against a standard preparation (Nutrizym GR).
• To evaluate clinical outcomes including weight gain, appetite, abdominal pain, stool consistency, and fecal fat in pediatric CF patients.

Main Methods:

• A randomized, double-blind, crossover study design was employed.
• Twenty-two pediatric patients with cystic fibrosis (aged 7-16 years) participated.
• Patients were switched between standard Nutrizym GR and double-strength Nutrizym 22 capsules over two 14-day periods.

Main Results:

• No statistically significant differences were observed in actual weight gain between the two preparations.
• Appetite, abdominal pain, stool consistency, and fecal fat levels showed no significant variations.
• The study demonstrated comparable efficacy for both pancreatic enzyme preparations.

Conclusions:

• Half the capsule number of the high-strength Nutrizym 22 preparation is as effective as the standard dosage of Nutrizym GR.
• This finding suggests potential for simplified dosing regimens in cystic fibrosis patients.
• Further research may explore long-term outcomes and patient-reported benefits of high-dose preparations.